From Yahoo News & Reuters, news of what – hopefully – can be a new treatment for Alzheimers.
“Eli Lilly and Co said on Monday a trial of its experimental Alzheimer’s drug donanemab showed it slowed by about a third the rate of decline in a combined measure of cognition and function in early-stage victims of the disease.
The drug is an antibody designed to remove clumps of the Alzheimer’s-related protein beta amyloid from the brain.”
As always we shouldn’t get too excited yet. The study involved fewer than 200 subjects, with a 500 person follow up study set to begin soon. But maybe a little excitement is warranted.
Brought to you bysmpltec.com, Technology for Seniors News.